Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic hepatitis C: updated Swedish consensus.

Rune Wejstål1, Annette Alaeus, Björn Fischler

  • 1Department of Infectious Diseases, Sahlgrenska University Hospital/Ostra, Göteborg, Sweden. rune.wejstal@vgregion.se

Scandinavian Journal of Infectious Diseases
|September 30, 2003
PubMed
Summary

Updated Swedish guidelines recommend pegylated interferon (peg-IFN) with ribavirin for chronic hepatitis C (HCV). Treatment duration and biopsy needs vary by genotype, with options for postponing therapy in certain cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antimicrobial Prophylaxis in Solid Organ and Hematopoietic Stem Cell Transplantation: A Survey Among Member Centers of the European Reference Network TransplantChild.

Pediatric transplantation·2026
Same author

Swedish guidelines for the management and treatment of patients with hepatitis D (delta) virus infection 2025.

Infectious diseases (London, England)·2025
Same author

Condition-Specific Growth Charts for Children With Alagille Syndrome.

JAMA network open·2025
Same author

Elevated Serum Bile Acids Predict Poor Liver Outcomes in Children With Alagille Syndrome: Results From the GALA Study Group.

Liver international : official journal of the International Association for the Study of the Liver·2025
Same author

Phenotypic Divergence of JAG1- and NOTCH2-Associated Alagille Syndrome & Disease-Specific NOTCH2 Variant Classification Guidelines.

Liver international : official journal of the International Association for the Study of the Liver·2025
Same author

Multicenter Study on Early Predictors of Biliary Atresia Outcomes.

Journal of pediatric surgery·2025

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Pharmacology

Background:

  • Swedish national expert panel previously issued hepatitis C (HCV) treatment recommendations in 1999.
  • Recent advancements include pegylated interferon (peg-IFN) and improved understanding of acute HCV and HCV-human immunodeficiency virus (HIV) coinfection.
  • An expert meeting in October 2002 led to an update of the Swedish recommendations.

Purpose of the Study:

  • To update national recommendations for chronic hepatitis C (HCV) treatment.
  • To incorporate new therapeutic options and knowledge into clinical practice.
  • To provide guidance on managing HCV based on genotype, coinfection status, and treatment response.

Main Methods:

  • Expert panel review of recent advancements in HCV treatment.

Related Experiment Videos

  • Development of updated treatment guidelines based on new evidence.
  • Recommendations tailored to specific patient populations including genotype, coinfection, and prior treatment history.

    • Main Results:

    • Pegylated interferon (peg-IFN) combined with ribavirin is now the standard treatment for chronic HCV.
    • HCV genotypes 2 and 3 can be treated for 24 weeks without liver biopsy due to high response rates.
    • Treatment postponement is suggested for genotype 1 with mild disease, awaiting better options.
    • Discontinuation of therapy is advised if viral load reduction is insufficient after 12 weeks.
    • HCV-HIV coinfected patients benefit from combination therapy, ideally with CD4 counts >350/ml and before antiretroviral treatment (ART).

    Conclusions:

    • The updated recommendations emphasize combination therapy with peg-IFN and ribavirin as the primary approach for chronic HCV.
    • Treatment strategies are refined based on viral genotype, patient history, and coinfection status.
    • Close monitoring is crucial for HCV-HIV coinfected patients on concurrent ART or with significant liver fibrosis due to toxicity risks.